文献类型：期刊文献

英文题名：Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5

作者：Zhang, Baolai[1];Zhang, Su[1];Zhu, Lijuan[1,2];Chen, Xue[1];Zhao, Yunfeng[1];Chao, Li[1];Zhou, Juanping[1];Wang, Xing[1];Zhang, Xinyang[1];Ma, Nengqian[1]

第一作者：Zhang, Baolai

通信作者：Zhang, BL[1]

机构：[1]Lanzhou Univ, Sch Basic Med Sci, Dept Pharmacol, Key Lab Preclin Study New Drugs Gansu Prov, Lanzhou, Gansu, Peoples R China;[2]Gansu Univ Chinese Med, Dept Pharmacol, Lanzhou, Gansu, Peoples R China

第一机构：Lanzhou Univ, Sch Basic Med Sci, Dept Pharmacol, Key Lab Preclin Study New Drugs Gansu Prov, Lanzhou, Gansu, Peoples R China

通信机构：[1]corresponding author), Lanzhou Univ, Sch Basic Med Sci, Dept Pharmacol, Key Lab Preclin Study New Drugs Gansu Prov, Lanzhou, Gansu, Peoples R China.

年份：2017

卷号：336

起止页码：1

外文期刊名：TOXICOLOGY AND APPLIED PHARMACOLOGY

收录：;Scopus(收录号：2-s2.0-85030834611);WOS:【SCI-EXPANDED(收录号:WOS:000416880000001)】；

基金：This research work was supported in part by Fundamental Research Funds of the Central Universities (No. lzujbky-2013-169).

语种：英文

外文关键词：Gastric cancer; Arginine methyltransferase inhibitor 1 (AMI-1); Protein arginine methyltransferase 5 (PRMT5); Histonemethylation; eIF4E

摘要：Arginine methylation is carried out by protein arginine methyltransferase (PRMTs) family. Arginine methyltransferase inhibitor 1 (AMI-1) is mainly used to inhibit type I PRMT activity in vitro. However, the effects of AMI-1 on type II PRMT5 activity and gastric cancer (GC) remain unclear. In this study, we provided the first evidence that AMI-1 significantly inhibited GC cell proliferation and migration while induced GC cell apoptosis, and reduced the expression of PRMT5, eukaryotic translation initiation factor 4E (eIF4E), symmetric dimethylation of histone 3 (H3R8me2s) and histone 4 (H4R3me2s). In addition, AMI-1 inhibited tumor growth, downregulated eIF4E, H4R3me2s and H3R8me2s expression in mice xenografts model of GC. Collectively, our results suggest that AMI-1 inhibits GC by downregulating eIF4E and targeting type II PRMT5.